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Abstract
Aims/hypothesis Dominantly acting loss-of-function muta-
tions in the ABCC8/KCNJ11 genes can cause mild
medically responsive hyperinsulinaemic hypoglycaemia
(HH). As controversy exists over whether these mutations
predispose to diabetes in adulthood we investigated the
prevalence of diabetes in families with dominantly inherited
ATP-sensitive potassium (KATP) channel mutations causing
HH in the proband.
Methods We studied the phenotype of 30 mutation carriers
(14 children and 16 adults) from nine families with
dominant ABCC8/KCNJ11 mutations. Functional conse-
quences of six novel missense mutations were examined by
reconstituting the KATP channel in human embryonic
kidney 293 (HEK293) cells and evaluating the effect of
drugs and metabolic poisoning on the channels using the
86Rb flux assay.
Results The mutant channels all showed a lack of
86Rb
efflux on exposure to the channel agonist diazoxide or
metabolic inhibition. In the families, dominant ABCC8/
KCNJ11 mutations were associated with increased birth-
weight (median + 1.56 SD score [SDS]). Fourteen children
had HH and five adults were reported with HH or
hypoglycaemic episodes (63%). Progression from hypogly-
caemia to diabetes mellitus occurred in two individuals.
Eight adults had a history of gestational diabetes in multiple
pregnancies or were diabetic (diagnosed at a median age of
31 years). Within these families, none of the 19 adults who
were not carriers of the ABCC8/KCNJ11 mutation was
known to be diabetic.
Conclusions/interpretation The phenotype associated with
dominant ABCC8/KCNJ11 mutations ranges from asymp-
tomatic macrosomia to persistent HH in childhood. In
adults, it may also be an important cause of dominantly
inherited early-onset diabetes mellitus.
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Hyperinsulinaemic hypoglycaemia (HH) occurs because of
inappropriate secretion of insulin by the pancreatic beta
cells. The congenital forms of HH (CHI) occur because of
defects in key genes involved in insulin secretion [1]. The
commonest and most severe forms of CHI are due to
mutations in the ABCC8 and KCNJ11 genes [2, 3],
encoding the sulfonylurea receptor 1 (SUR1) and inward
rectifier K(+) channel Kir6.2 (Kir6.2) subunits of the ATP-
sensitive potassium (KATP) channel, respectively. The KATP
channels play a pivotal role in glucose-stimulated insulin
secretion and couple glucose metabolism to membrane
electrical activity and insulin release in the pancreatic beta
cells [4].
Recessively inherited inactivating ABCC8/KCNJ11
mutations usually cause medically unresponsive disease.
The molecular basis of the CHI observed in these patients
involves defects in the biogenesis and turnover of KATP
channels, in the trafficking of channels to the plasma
membrane and alterations in the open-state frequency
through changes in nucleotide sensitivity [5–8].
Dominant ABCC8/KCNJ11 mutations are less frequently
reported and generally cause mild medically responsive HH
[9–12] or in rare cases, severe unresponsive HH [13]. Two
reports suggest that medically responsive HH due to a
dominantly inherited ABCC8 mutation may progress to
diabetes mellitus (DM) in later life [9, 12, 14]. However,
this was not supported in a recent case series where only 4
out of 29 adult mutation carriers developed DM [11].
Hence, it is not clear whether dominantly acting mutations
in the genes that cause diazoxide-responsive HH in
childhood are associated with later development of DM in
adulthood.
In this study, we present the phenotype of eight different
heterozygous ABCC8/KCNJ11 mutations in nine families
and report the prevalence of DM in the adult mutation
carriers. We show that dominant mutations can cause a
variable phenotype ranging from asymptomatic macro-
somia to transient/persistent HH as well as progression to
DM in later life.
Methods
Patients Nine families with dominant KATP channel muta-
tions were studied. The probands are a subgroup of children
referred to the tertiary Hyperinsulinism Service at Great
Ormond Street Hospital NHS Trust, London, UK. They
include those children with HH who were diazoxide
responsive and were identified to be heterozygous for a
KATP channel mutation. The diagnosis of HH was based on
diagnostic criteria described previously (i.e. inappropriately
elevated insulin concentrations at the time of hypoglycae-
mia with corresponding low concentrations of plasma
β-hydroxybutyrate and fatty acids). Diazoxide responsive-
ness was defined as the ability to maintain normoglycaemia
without the support of intravenous glucose. Clinical
information (birthweight, age at presentation, treatment
details of HH) was collected from the case notes and the
referring clinicians. Family history was specifically explored
with regards to symptoms of hypoglycaemia and presence/
absence of DM and phenotypic details of individuals affected
by hypoglycaemia/DM (birthweight, age of presentation,
treatment details) was collected. The Office for National
Statistics(ONS)classificationwasusedtocategoriseethnicity
[15]. The study was approved by the regional ethical
committee and written consent was obtained from the
families.
Genetic analysis Genomic DNA was extracted from
peripheral leucocytes using standard procedures. The
single exon of the KCNJ11 gene and the 39 exons of
ABCC8 were amplified by PCR using previously reported
primers [16]. Single-strand sequencing was carried out
using standard methods and an ABI3730 capillary sequencer
(Applied Biosystems, Warrington, UK) and sequences were
compared with the published sequences (NM_000525 and
NM_000352.2 [which incorporates the alternatively spliced
amino acid in exon 17 {L78224}]) using Mutation Surveyor
3.24 software (SoftGenetics, State College, PA, USA).
Following identification of a mono-allelic KATP channel
mutation in the proband, parents were tested to establish
the mode of inheritance. Microsatellite analysis (PowerPlex
16 System, Promega, Southampton, UK) was undertaken to
confirm family relationships when a de novo mutation was
identified. Genetic analysis was then offered to the siblings
of the proband (parental consent obtained) and to the siblings
and parents of the parent identified as heterozygous for the
mutation. Co-segregation studies were then undertaken with
the available phenotypic data and results of the genetic
analysis.
Functional analysis of mutant channels Functional analysis
of the novel ABCC8 mutations (A1508P, A1537V, L1431F,
L1390R and Q1459E) and the KCNJ11 mutation (I284del)
was carried out. Mutations were introduced in hamster Sur1
(also known as Abcc8) cDNA and mouse Kir6.2 (also
known as Kcnj11) cDNA using the Quik-change site-
directed mutagenesis kit (Agilent Technologies, Stockport,
UK). Mutant KATP channel was reconstituted in human
embryonic kidney 293 (HEK293) cells by transfection
using FuGene HD (Roche, Burgess Hill, UK) according to
the manufacturer’s instructions. Enhanced green fluorescent
protein, 50 ng, was also co-transfected to determine
transfection efficiency.
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86Rb flux assay
was used to determine functionality of the reconstituted
channels as described previously by Muzyamba et al. [17].
The
86Rb efflux assay is based on the principle that when
cells are loaded with rubidium, its distribution between
intracellular and extracellular spaces is an indicator of
channel activity as
86Rb is similar in size and charge to K
+
and is handled by the channels in a manner similar to K
+.
Briefly, 24 h after transfection cells were incubated overnight
with minimum essential medium (MEM) containing
86Rb
(0.037 MBq/ml) at optimum conditions (5% CO2,3 7 ° C ) .
The assay medium was then aspirated and the cells were
washed twice with 2 ml HEPES buffered NaCl (HBS)
(10 mmol/l HEPES, 10 mmol/l glucose, 130 mmol/l NaCl,
7 mmol/l KCl, 2 mmol/l CaCl2 and 1 mmol/l MgCl2,
pH 7.4) [17]. The cells were then incubated with 2 ml of
HBS medium with or without channel stimulants and/or
inhibitors. The following conditions were used: control cells
(no drugs); cells treated with 100 μmol/l diazoxide; cells
treated with 100 μmol/l diazoxide plus 10 μmol/l glibencla-
mide; cells treated with 2.5 mmol/l NaCN (sodium cyanide)
and 20 mmol/l 2-deoxy-D-glucose; and cells treated with
2.5 mmol/l NaCN, 20 mmol/l 2-deoxy-D-glucose and
10 μmol/l glibenclamide. The concentrations of the drugs
stated have been shown to be effective on this cell line [17].
The supernatant fraction was aspirated after 5 min into
scintillation vials for counting and the cells were then lysed
with 2% Triton/HBS solution. Cherenkov radiation in the
supernatant fraction and cell lysates was measured and the
efflux was calculated as a percentage relative to the total
amount of radioactivity incorporated. The data are presented
as mean ± SEM. Significant differences were tested by
employing the one-way ANOVA and Bonferroni post-test.
Significant differences are reported as: *p≤0.05, **p≤0.01
and ***p≤0.001.
The level of mutant protein produced in the transfected
cells was detected using western blotting. The antibody
anti-SUR1 NBD2 was raised in sheep to the peptide epitope
ETLLSQKDSVFASFVRADK (University of Dundee,
Dundee, UK) and subsequently used as described previously
by Muzyamba et al. [17]. An anti-sheep IgG secondary
antibody (Sigma, Poole, UK) linked to horseradish peroxi-
dase and the ECL detection kit (GE Healthcare, Amersham,
UK) were used to detect protein production.
OGTT and BMI The adult mutation carriers were divided
into those with a history of DM (gestational or other, n=8)
and those without (n=8). A 2 h OGTTwas conducted in the
relatives of adult mutation carriers who had no history of
DM to ensure that undiagnosed impaired glucose tolerance/
DM was detected. Patients with ongoing hypoglycaemia
(II-2, family A and III-2, family F [Fig. 1]) were excluded.
Six adults met the criteria but one participant (II-1, family E
[Fig. 1]) was not contactable. Blood glucose concentrations
were measured at 0 and 120 min following an oral load of
glucose (75 g) in the remaining five adult mutation carriers.
The BMI of the adult mutation carriers with normal glucose
tolerance (n=5) and with DM (n=8) was calculated and the
means were compared using the Student’s t test.
Results
Genetic analysis Seven different heterozygous ABCC8
mutations were identified in eight probands. Five of the
mutations were novel (L1390R, L1431F, Q1459E, A1508P
and A1537V) and two have been reported previously in
patients with dominantly inherited HH (G1479R and
R1539Q) [11]. Each mutation was identified in a single
family with the exception of G1479R, which was identified
in two unrelated families. All mutations affected residues
that are highly conserved across species and occurred
within nucleotide-binding domain 2 of SUR1, a previously
reported hotspot for dominantly acting mutations. The
remaining proband was heterozygous for an in-frame
deletion (I284del) in the KCNJ11 gene.
Of the 35 adult family members (including 18 parents)
and eight siblings screened for the identified mutation, 16
adults and five siblings tested positive. This included eight
parents, of whom seven were affected with hypoglycaemia
or DM. In the remaining case (family C) although the
mutation (G1479R) had been inherited from the unaffected
father it was shown to co-segregate with HH in the family
having been identified in the proband’s two affected
siblings and paternal cousin. In two families there was no
history of hypoglycaemia or DM (Fig. 1, family I and J).
Confirmation of family relationships by microsatellite
analysis demonstrated that the L1390R and G1479A
mutations had arisen de novo in the proband.
Functional analysis of mutant channels The R1539Q and
G1479R ABCC8 mutations have been characterised previ-
ously by Pinney et al. [11] and hence these mutations were
excluded from functional studies. The
86Rb flux assay
showed that the channels with the mutant proteins (SUR1
[A1508P, L1431F, L1390R, Q1459E or A1537V] or Kir6.2
[I284del]) were non-functional as evidenced by the lack of
86Rb efflux on exposure to the channel agonist diazoxide or
metabolic inhibition (Fig. 2a–g). Production of the mutant
SUR1 proteins L1431F, L1390R, Q1459E and A1537V did
not differ from the wild-type SUR1 protein on western blot
analysis (Fig. 2h).
Clinical characteristics of children with HH The clinical
characteristics of the 14 children with HH (nine probands
and five affected siblings) are summarised in Table 1. The
Diabetologia (2011) 54:2575–2583 2577median age at presentation was 1 day and median birthweight
was +2.21 SD score (SDS). Hypoglycaemia resolved within
1 week in one case but the remaining children (aged 1–
11 years) received ongoing diazoxide treatment.
Phenotype of the adult mutation carriers The median
birthweight of the adult mutation carriers (n=16; data
available for ten individuals) was high at +1.39 SDS (ranging
from −2.11SDS to +2.45SDS, Table 2). Interestingly, five of
the six adult mutation carriers who were macrosomic at birth
developed hypoglycaemia. Two of these had persisting
hypoglycaemia at 28 and 39 years of age (Fig. 1: family A,
II-2 and family F, III-2), whilst one had a history of transient
neonatal hypoglycaemia (Fig. 1: family E, II-1) (Table 2).
Two other adults had a past history of hypoglycaemia that
progressed to DM (family B II-2 and family H III-2).
Of the remaining 11 adult mutation carriers, there was a
history of diabetes (gestational or other) in six further
individuals (family A, II-3; family D, II-2; family G, III-5;
family F, II-4 and III-4; and family H, II-2). The remaining
five adults (family A I-2, family C I-2, II-2, II-3 and family
F III-3) had no history of hypoglycaemia/DM. In total, 5/16
adult mutation carriers had or had had hypoglycaemia and
eight either had gestational diabetes (GDM) in multiple
pregnancies or were currently diabetic. The age at diagnosis
of DM ranged from 20 to 50 years with a median of
31 years (see Table 2). None of the 19 adult family
members (aged 20–68 years, median 40 years) who did not
carry the ABCC8/KCNJ11 mutation were known to be
affected with diabetes (Fig. 1).
According to the WHO criteria none of the five
asymptomatic adult mutation carriers investigated had
impaired fasting glucose/impaired glucose tolerance or
DM. There was no significant difference in the mean BMI
of the adult mutation carriers who developed DM from
those who did not (p=0.7).
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Fig. 1 Partial pedigrees showing inheritance of the dominant
mutations in the ten families. Circles represent females and squares
indicate males. An arrow indicates the proband. Vertical hatching
denotes diabetic individuals and diagonal hatching represents individ-
uals with GDM. Black symbols denote children/adults with hypo-
glycaemia. Individuals who progressed from hypoglycaemia to
diabetes are indicated by symbols that are half-filled and half-
hatched vertically. The genotype is given below each symbol. M/N
denotes a heterozygous ABCC8/KCNJ11 mutation and N/N a normal
genotype. The KCNJ11 mutation is indicated by *; the remaining are
ABCC8 gene mutations
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This case series reports the phenotype of eight (six novel)
dominant ABCC8/KCNJ11 mutations. We identified 30
individuals (14 children and 16 adults) with heterozygous
KATP channel mutations from ten families. Nineteen of the
30 (63%) had a past/current history of hypoglycaemia and
eight adults (50%) had a history of gestational diabetes in
multiple pregnancies or were currently diabetic.
The hyperinsulinaemic phenotype of these mutations
was mild and diazoxide responsive, as reported in the
literature previously [9, 11, 12]. Of the 14 children, 13
required treatment with diazoxide, whilst the remaining had
transient hypoglycaemia that remitted in the neonatal
period. These included a pair of siblings (family F
[Fig. 1]) heterozygous for the R1539Q mutation in the
ABCC8 gene who had hypoglycaemia for different dura-
tions. The older sibling required brief treatment with
intravenous glucose after birth while the younger sibling
continued to require diazoxide therapy at 3 years of age,
demonstrating the variability in the phenotype of HH within
the same family.
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Fig. 2 a–g Effects of SUR1/Kir6.2 mutants on KATP channel function
studied with
86Rb efflux. The
86Rb efflux was assayed 48 h after
transfection in control cells (horizontal hatching, no drugs), cells
treated with 100 μmol/l diazoxide (diagonal hatching), cells treated
with 100 μmol/l diazoxide plus 10 μmol/l glibenclamide (vertical
hatching), cells treated with 2.5 mmol/l NaCN and 20 mmol 2-deoxy-
D-glucose (black) and cells treated with 2.5 mmol/l NaCN, 20 mmol/l
2-deoxy-D-glucose and 10 μmol/l glibenclamide (white). (a) Wild
type; (b) L143F (ABCC8); (c) A1508P (ABCC8); (d) I284del
(KCNJ11); (e) L1390R (ABCC8); (f) Q1459E (ABCC8); (g) A1537V
(ABCC8). Data represent means ± SEM for three different experiments
performed in triplicate (n=9); ***p<0.001. h Western blot analysis of
SUR1 shows that the production of the mutant SUR1 proteins
L1431F, L1390R, Q1459E and A1537V did not differ from the WT
SUR1 protein (177 kDa). WT, wild type
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Family Individual/sex Mutation/gene Birthweight
SDS
Age at
presentation
Diazoxide
responsive
Length of treatment
with diazoxide
A III-1/female A1537V (c.4610C>T)/ABCC8 +4.66 1 day Yes Continuing at 4 years
B III-3/female G1479R (c.4435G>A)/ABCC8 +1.37 1 day Yes Continuing at 11 years
C III-1/male G1479R (c.4435G>A)/ABCC8 +2.82 1 day Yes Continuing at 1.4 years
C III-2/female G1479R (c.4435G>A)/ABCC8 +1.65 2 days Yes Continuing at 8.5 years
C III-3/male G1479R (c.4435G>A)/ABCC8 +2.23 2 days Yes Continuing at 5.1 years
C III-4/female G1479R (c.4435G>A)/ABCC8 +1.93 2 days Yes Continuing at 1.5 years
D III-1/female Q1459E (c.4375C>G)/ABCC8 +3.14 1 day Yes Continuing at 5.8 years
D III-2/male Q1459E (c.4375C>G)/ABCC8 +2.52 1 day Yes Continuing at 6 weeks
E III-1/female I284del (c.850_852del)/KCNJ11 +1.48 1 day Yes Continuing at 1.8 years
F IV-3/male R1539Q (c.4616G>A)/ABCC8 +2.19 1 day Yes Continuing at 3.2 years
F IV-2/male R1539Q (c.4616G>A)/ABCC8 +0.07 1 day NA NA
G IV-1/male L1431F (c.4291C>T)/ABCC8 −0.98 1 year Yes Continuing at 2.5 years
H IV-1/male A1508P (c.4522G>A)/ABCC8 +4.09 1 day Yes Continuing at 9.2 years
I II-1/female L1390R (c.4619T>G)/ABCC8 +3.22 1 day Yes Continuing at 11 years
NA, not applicable, as had transient hypoglycaemia that did not require treatment with diazoxide
Table 2 Summary of the clinical features of the adult mutation carriers
Family Patient/ethnicity Current
age (years)
BMI
(kg/m
2)
BW
SDS
Hypoglycaemia/
past or current
Diabetes
a Treatment
b OGTT blood glucose
b
(mmol/l)
Fasting 2 h
A II-2/white British 28 21 +1.42 Yes, current NA Nil NA NA
A II-3/white British 30 26.2 +1.23 No Yes, GDM at 26
and 29 years
Dietary NA NA
A I-2/white British 57 21 – No No NA 4.0 5.3
B II-2/white British 44 33 +1.4 Yes, past Yes, GDM at
23 years, overt
diabetes at 30 years
Insulin (metformin
tried initially)
NA NA
C I-2/white Irish 73 32.2 – No No NA 4.9 4.9
C II-2/white Irish 32 31.4 +0.35 No No NA 4.8 7.2
C II-3/white Irish 37 29.6 −2.11 No No NA 5.4 4.4
D II-2/white British 30 23 – No Yes, GDM at 21,
23 and 25 years
Insulin during
pregnancies
NA NA
E II-1/white British 20 – +2.07 Yes, past Not known i.v. glucose
for neonatal
hypoglycaemia
Not known Not known
F II-4/white Irish 72 23.7 – No Yes, 47 years Metformin+
gliclazide
NA NA
F III-2/white Irish 39 21.6 +2.45 Yes, current NA Nil NA NA
F III-3/white Irish 35 25.1 −0.39 No No NA 3.7 7.0
F III-4/white Irish 40 42.2 −0.58 No Yes, GDM at
36 years, overt
diabetes at 39 years
Metformin NA NA
G III-5/black African 43 24.9 – No Yes, 20 years Insulin NA NA
H II-2/white British 65 28.4 – No Yes, 50 years Insulin NA NA
H III-2/white British 40 31.1 +1.38 Yes, past Yes, 38 years Metformin NA NA
aYes/no in the case of normal OGTT and, if yes, age of diagnosis is shown; NA if current hypoglycaemia
bIf applicable
BW, birthweight; NA, not applicable; Nil, hypoglycaemia not requiring treatment with drugs
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have had hypoglycaemic episodes after the diagnosis of HH
in their children. Three others had a previous history of
hypoglycaemia; of these individuals, one had had transient
neonatal hypoglycaemia treated with intravenous glucose,
while the other two had had more persistent hypoglycaemia
that remitted in young adulthood. The remaining adult
mutation carriers (11/16) had no current/past history of
hypoglycaemia. This is consistent with the study by Pinney
et al. in which 14/29 adults were asymptomatic [11]. The
incomplete penetrance of hypoglycaemia is not mutation
specific. Nevertheless, in utero hyperinsulinism was evident
from the higher birthweights of the mutation carriers.
Hence, these dominant KATP mutations result in a varied
phenotype, ranging from asymptomatic macrosomia to
persistent HH requiring diazoxide treatment. In contrast to
the paper by Huopio et al. [9], in which all the patients
inherited their mutation from their mothers, our probands
inherited the mutations from either the maternal or paternal
allele, refuting the possibility of a parent-of-origin effect or
an imprinting defect.
It has been debated whether dominant KATP channel
mutations causing HH predispose to the development of
DM in adulthood [9, 11, 14, 18]. Huopio et al. first reported
a dominant inactivating ABCC8 mutation, E1506K
(E1507K according to reference sequence NM_000352.2),
that caused HH progression to hypoinsulinaemic DM
during middle age [9, 14]. In their study, adults heterozy-
gous for this particular mutation showed reduced insulin
secretory capacity and only 1/11 adults had normal glucose
tolerance [14]. In addition, the individuals who developed
DM had reduced insulin sensitivity (3/4 individuals with
DM were overweight). The authors hypothesised that the
primary insulin secreting defect may be related to beta cell
apoptosis due to raised intracellular calcium concentrations
and that the accompanying insulin resistance may be the
reason for conversion from impaired glucose tolerance to
DM. Another family with this mutation has recently been
reported with HH in childhood and later-onset diabetes
[19] .I n t e r e s t i n g l y ,i n s u l i nd e f i c i e n c yi so b s e r v e di nt h e
beta cell-specific dominant-negative Kir6.2 mouse [20].
Furthermore, Abdulhadi-Atwan et al. described a patient
with HH due to a de novo ABCC8 mutation who presented
with DM at 10.5 years of age [12]. This child was obese
(BMI 30.2 kg/m
2), supporting the hypothesis that insulin
resistance in conjunction with a dominant KATP channel
mutation can predispose to the development of DM.
However, a recent study that looked at the prevalence of
DM in a large number of families with dominant KATP
channel mutations [11] reported diabetes in just 13.8% of
the adult carriers. The prevalence of DM in this cohort was
comparable with the estimated prevalence of type 2 DM in
adults in the USA, which ranges from 9.6% to 21% [21]. In
contrast we identified two adults who developed DM in
adulthood following hypoglycaemia in early life and six
adults who were diagnosed with either GDM or overt
diabetes before the age of 50 years. Excluding the two
adults who had symptoms of hypoglycaemia at the time of
the study, the prevalence of DM (gestational or other) was
high, with 8/14 adult mutation carriers being affected in our
cohort. This may even be an underestimate as some
individuals who do not have DM may go on to develop it
later. In contrast, none of the 19 adult non-carriers of the
ABCC8/KCNJ11 mutation within these families were
known to be diabetic.
The difference in the reported prevalence of diabetes
in the adult mutation carriers in our study and that of the
US study [11] can be partly explained. First, there were a
high percentage of adults with ongoing hypoglycaemia
(51%) in the American study. The presence of hypogly-
caemic symptoms in these adults signifies the persistence
of hyperinsulinism. Surprisingly, these adults were not
excluded from the final analysis of the adults affected with
DM. Second, adults with GDM were excluded from the
final reporting of patients with DM. The authors argue that
the development of GDM in adults with a dominant KATP
channel mutation may not have the same implication for
the eventual development of diabetes as it may reflect
impaired glucose-stimulated insulin release due to a direct
consequence of defective KATP channel activity [11].
However, GDM per se forms an important diagnosis and
has implications for the management of the individual
during her pregnancy and for the growing fetus. Hence,
we believe that the increased risk of GDM merits reporting
in this study.
However, it is also clear that not all adult mutation
carriers develop DM. We confirmed normal glucose
tolerance in five of the adults who had no history of DM.
In our cohort, the mean BMIs of those with normal glucose
tolerance (n=5) and those with DM (n=8) were not
significantly different. Nevertheless, the adults who devel-
oped overt diabetes following GDM in multiple pregnancies
did have higher BMIs (33 and 42.2 kg/m
2) than those adults
who did not develop overt diabetes following GDM (23 and
26 kg/m
2). However, these data must be interpreted with
caution as the number of individuals in each group was
small. In addition, patients with the same G1479R mutation
hadvariedglucose tolerance,suggestingthatthe development
of DM is not mutation specific and other environmental/
genetic factors may be involved.
This study confirms that dominant ABCC8/KCNJ11
mutations can lead to a variable phenotype of neonatal
HH, impaired glucose intolerance and diabetes mellitus
later in life. The mechanistic explanation for the neonatal
HH involves subtle defects in the function of KATP
channels. We carried out Rb flux assays to prove the
Diabetologia (2011) 54:2575–2583 2581pathogenicity of the novel mutations identified in the study.
The homozygous in vitro model was not stimulated by the
KATP channel agonist diazoxide, a finding which is
consistent with these mutations being disease causing.
Western blotting confirmed that the mutant SUR1 proteins
were produced in the cell (Fig. 2b). In patients with
dominant ABCC8/KCNJ11 mutations, KATP channels are
assembled from mutant and wild-type SUR1 and KIR6.2
subunits (channel hetero-octomers are formed with zero to
four SUR1 and KIR6.2 mutant subunits). The eventual
KATP channel activity is based on the number of mutant
subunits present (in the complex consisting of both mutant
and wild-type subunits) and the extent to which the mutant
subunit exerts its adverse effect on channel activity. The
resulting impairment in channel activity is sufficient to
activate the downstream voltage-gated calcium channels
and thus trigger unregulated insulin secretion. These
patients respond to diazoxide presumably because some
wild-type SUR1 subunits are present and allow diazoxide
activation. The milder phenotype of dominant mutations
reflects the subtle KATP channel defect in comparison with
recessive mutations, which lead to defects in channel
biogenesis, trafficking and assembly.
The mechanism of glucose intolerance and diabetes
mellitus in patients with dominant ABCC8/KCNJ11 muta-
tions is not so clear at present. Possible explanations
include a progressive failure in beta cell function due to
‘exhaustion’, increased beta cell apoptosis as a result of
raised intracellular calcium concentration and the influence
of other genetic or environment factors. Further studies are
required to understand how these mutations cause glucose
intolerance and diabetes later in life.
Conclusion
Dominant mutations in ABCC8/KCNJ11 cause a varying
phenotype ranging from asymptomatic macrosomia to
persistent HH in childhood. There is an increased risk of
DM in the adult mutation carriers. This has important
implications for follow up of children with dominantly
acting ABCC8/KCNJ11 mutations and the management of
the adult carriers.
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